Cognitive Function in Primary Sjögren’s Syndrome: A Systematic Review

Ciro Manzo,1,2,* Eva Martinez-Suarez,3 Melek Kechida,4 Marco Isetta,5 and Jordi Serra-Mestres6

1 Rheumatologic Outpatient Clinic and Gerontorheumatology Service, “Mariano Lauro” Hospital, 80065 Sant’Agnello, Italy
2 Center for Cognitive Diseases and Dementias, Azienda Sanitaria Locale Napoli 3 sud, 80038 Pomigliano d’Arco, Italy
3 Geriatrician, Hospital de Mataró (Barcelona), 08304 Mataró, Barcelona, Spain; emartinezsu@csdm.cat
4 Internal Medicine and Endocrinology Department, Fattouma Bourguiba University Hospital, University of Monastir, 5000 Monastir, Tunisia; kechida_mel_lek@hotmail.com
5 Library and Knowledge Services, Central and North West London NHS Foundation Trust, London UB8 3NN, UK; marco.isetta@nhs.net
6 Department of Old Age Psychiatry, Central and North West London NHS Foundation Trust, London UB8 3NN, UK; jordi.serra-mestres@nhs.net

* Correspondence: cirmanzo@libero.it; Tel.: +39-081-329-6402; Fax: +39-081-533-1447

Received: 18 March 2019; Accepted: 9 April 2019; Published: 15 April 2019

Abstract: Background: Cognitive disorders are reported to be common in patients with primary Sjögren’s syndrome (pSS). In some cases, they are the first clinical manifestation, preceding the diagnosis of pSS by two years on average. Aim: A systematic review was conducted to explore cognitive impairment in pSS, with reference to diagnostic methods and their relationship with laboratory data and clinical manifestations. Materials and Methods: According to the PRISMA 2009 checklist, we carried out a comprehensive literature search in the three main bibliographic databases: MEDLINE, EMBASE, and PsycINFO (NICE HDAS interface). The following main search terms were used: primary Sjögren syndrome, neurological manifestations, fatigue, cognitive functions, psychiatric manifestations, mild cognitive impairment, dementia, and neurocognitive disorder. The search was made on 14 September, 2018. References from all selected studies were also examined. Inclusion criteria were: all studies and case-reports published in any language from 2002 that assessed the association of pSS (according to classification criteria proposed by the 2002 American/European collaborative group (AECG)) with all types of cognitive impairment (including dementia). Exclusion criteria were: reviews, abstracts, secondary Sjögren’s syndrome (SS), and all articles in which other classification criteria were used. Results: The initial search yielded 352 articles, of which 253 were excluded based on the title and abstract review. A total of 54 articles underwent a full-length review, and 32 articles were excluded. Data were extracted from 18 studies and three case-reports involving a total of 6196 participants. In most cases, cognitive dysfunction was a brain fog or a mild cognitive impairment (MCI). Occasionally, an autoimmune dementia was present. The relationship between pSS and degenerative dementias, such as Alzheimer’s disease (AD), was a controversial issue, even if some investigators hypothesized that pSS could be a risk factor. Several unmet needs were highlighted. First, some of the included studies had not reported the severity of pSS; hence, few correlations between disease severity and cognitive function were possible. Secondly, the evaluation of the pathogenetic role of comorbid diseases was often absent. The lack of information on the type of dementia represented a third critical point in the majority of the included studies. Conclusions: This systematic review confirmed that adequate studies on cognitive function in pSS are scarce, mostly performed on small-sized samples, and often conflicting. The routine assessment of cognitive function in patients with pSS seems advisable and it will help to elucidate some of the unmet needs highlighted by this review in future appropriately designed studies.
Keywords: primary Sjögren’s syndrome; cognitive functions; mild cognitive impairment; brain fog; dementia; fatigue; systematic review

1. Introduction

1.1. Rationale

Sjögren’s syndrome (SS) is one of the most common connective tissue diseases. It typically presents with a lymphocytic infiltration of exocrine glands leading to sicca syndrome. SS can be present as primary SS (pSS), which is an entity by itself without an underlying autoimmune condition, or secondary SS (sSS) [1–3]. At least one-third of patients with pSS can present with extraglandular involvement, with neurological dysfunction being one of the most frequent conditions [4,5]. The rate of neurological symptoms in patients with pSS has been reported to range from 8.5% to 70%. Such a disparate range is a likely consequence of the use of different sets of diagnostic criteria for pSS and of different definitions of neurological syndromes. However, the diagnostic set is important, as there is a greater availability of evaluations of neurological function in patients hospitalized on neurology wards, compared with rheumatology wards [6,7]. The most frequent neurological complication of pSS is peripheral neuropathy, especially sensory polyneuropathy. Central nervous system (CNS) involvement is much less common and has been reported in less than 25% of patients. Simultaneous involvement of the peripheral and the central nervous systems is also possible [8]. In 25–60% of cases, neurological symptoms are the first clinical manifestation and can precede the diagnosis of pSS on an average of two years [9]. Cognitive disorders are reported to be common. Many patients reported mild or minimal subjective cognitive difficulties, often referred to as the so-called “brain-fog”. Brain fog represents a wide range of subjectively experienced cognitive difficulties, such as forgetfulness, memory lapses, mental confusion, reduced verbal fluency, and diminished ability to concentrate more severely in the presence of distractors or competing stimuli [10,11]. Sometimes, cognitive impairment has been thought to be a consequence of other manifestations of pSS, such as fatigue. Fatigue can be defined as an enduring, subjective sensation of generalized tiredness or exhaustion. Unlike weakness, fatigue can be alleviated by periods of rest. Most patients with rheumatic diseases complain of chronic fatigue [12]. Moreover, the relationship between pSS and the dementias, especially Alzheimer’s disease (AD), must be better assessed.

1.2. Objectives

A systematic review was conducted to explore cognitive impairment in pSS, with emphasis on diagnostic methods and their relationship with laboratory data and with clinical manifestations. The relationship between pSS and dementias and the role of fatigue were the review’s main focus.

2. Materials and Methods

This systematic review was conducted and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. No review protocol exists.

2.1. Search Strategy

One author of this study (Isetta, M.) carried out a comprehensive literature search in the three main bibliographic databases: MEDLINE, EMBASE, and PsycINFO (NICE HDAS interface). The following main search terms were used: primary Sjogren syndrome, neurological manifestations, fatigue, cognitive functions, psychiatric manifestations, mild cognitive impairment, dementia, and neurocognitive disorder. The search was made on 14 September, 2018. References from all of the selected studies were also examined. In accordance with the PRISMA 2009 checklist [13], the full search terms used, together with the results of the searches in one of the three databases (MEDLINE), are detailed in the Supplemental material and methods section.
2.2. Inclusion Criteria

This review included all studies and case-reports published in any language from 2002 that assessed the association of pSS (according to classification criteria proposed by the 2002 American/European collaborative group (AECG)) with all types of cognitive impairment (including dementia). According to these criteria, the diagnosis of pSS can be made by fulfilling four out of six items. Two items include subjective xerophthalmia and xerostomia; two items include objective evidence of keratoconjunctivitis sicca and xerostomia; two items include a positive minor salivary gland biopsy with a focus score of ≥1/4 mm² or the presence of anti-Ro(SSA) or anti-La(SSB) antibodies [14].

In 2012, new criteria were proposed by the Sjögren’s International Collaborative Clinical Alliances Cohort [15] and then approved in 2016 by the American College of Rheumatology (ACR) and by the European League against Rheumatism (EULAR). These classification criteria are based on the weighted sum of five items: anti-SSA/Ro antibody positivity and focal lymphocytic sialadenitis with a focus score of ≥1 foci/4 mm², each scoring 3; an abnormal ocular staining score of ≥5 (or van Bijsterveld score of ≥4); a Schirmer’s test result of ≤5 mm/5 min; and an unstimulated salivary flow rate of ≤0.1 mL/min, each scoring 1. Individuals with signs or symptoms suggestive of SS, or both, who have a total score of ≥4 for the above items meet the criteria for primary SS [16]. Level of agreement between these criteria sets has been evaluated as excellent [17], but the real life application of the 2016 ACR/EULAR criteria is still infrequent [18].

2.3. Exclusion Criteria

Reviews, abstracts, and sSS were excluded from this review. All articles in which other classification criteria were used were also excluded.

2.4. Data Extraction

Two authors of this study (Martinez-Suarez, E. and Manzo, C.) independently reviewed the titles and abstracts of all identified citations. After reviewing the abstracts, data comparisons were conducted to ensure completeness and reliability. The inclusion criteria were independently applied to all identified studies. Differing decisions were resolved by consensus. Full-text versions of potentially relevant papers identified in the initial screening were retrieved. Data concerning study design, source of information, participant characteristics, SS, and assessment of cognitive function were independently extracted.

2.5. Assessment of Bias Risk

A subjective assessment of the methodological quality of observational studies was performed by all the authors using the Newcastle-Ottawa Scale, which is a quality assessment tool for non-randomized studies [19]. It uses a “star system” based on three major perspectives: the selection of the study groups (0–4 stars, or 0–5 stars for cross-sectional studies), the comparability of the groups by controlling for important and additional relevant factors (0–2 stars), and the ascertainment of the outcome of interest or exposure (0–3 stars). A total score of 3 or less was considered poor, 4–6 was considered moderate, and 7–10 was considered high quality. Studies scoring 3 or less were excluded from our review. Discrepant opinions between authors were resolved by consensus.

3. Results

3.1. Description of Included Studies

As reported in Figure 1, the initial search yielded 352 articles, of which 253 articles were excluded based on the title and abstract review. A total of 54 articles underwent a full-length review, and 32 articles were excluded (not a study in subject of interest = 5; studies having poor quality = 10; no outcome of interest = 18). Data were extracted from 18 studies and 3 case-reports, involving a total of 6196 subjects.
The characteristics of studies included in this review are outlined in Table 1.
Table 1. Characteristics and main data of the studies included in this review.

| 1st Author Year | Study Design | Patients F/M | Cognitive Impairment | Depression | Fatigue | Subset of Cognitive Impairment | Neuro Imaging | Correlation with Extraglandular Manifestations |
|----------------|--------------|--------------|----------------------|------------|---------|-------------------------------|--------------|-----------------------------------------------|
| Segal BM, 2012 [20] | Case-control Monocentric data | 39/39 | YES 30% psychomotor processing (DST verbal reasoning; similarities) | Yes, CES-D 47% vs. 6% | Yes, FSS | Frontal and subcortical brain type | Absent | No |
| Le Guern V, 2009 [21] | Case-control Monocentric data | 10/0 | YES 80% visuospatial abilities executive function | Yes Hamilton depression scale | No | Frontal-lobe-related syndrome | MR and 99m Tc-ECD SPECT | Yes 7/10 patients 1 positive for antiphospholipid serology and obstetric APLS 3 still active |
| Tezcan ME, 2016 [22] | Case-control Monocentric data | 28/28 | YES 78.6% immediate verbal memory Clock drawing test attention and information processing speed verbal learning | Yes | Yes | Frontal and subcortical brain type 3/28 (11%) with serious cognitive dysfunction, 11 (39.3%) with MCI, 8 (28.5%) had moderate cognitive dysfunction | Absent | Yes 2/28 patients - One patient liver and one patient lung involvement Antiganglioside antibody 42.8% No active extraglandular manifestation during neurological assessment |
| Delalande S, 2004 [23] | Retrospective study Monocentric data | 82/65/17 | YES Authors did not systematically screen their patients with pSS for cognitive impairment. | No | No | Not clear In 2 patients, subcortical dementia | Yes Brain MRI | Yes 71/86 in 47% of patients absence of sicca symptoms |
| Rodrigues DN, 2014 [24] | Case-control Monocentric data | 18/18 | YES Executive functioning Long-term memory tests | Yes Beck Depression Inventory | No | Subcortical brain type | Not reported | No |
| Morruale M, 2015 [25] | Case-control Monocentric data | 87/78/9 | Yes 31.1% Executive dysfunction Visuospatial disorders Short-term memory deficits | Yes Beck Depression Inventory | Not clear | Patients with recent diagnosis (<6 months) of pSS | Yes Brain MRI Transcranial Doppler | Yes |
| Yoshikawa K, 2012 [26] | Prospective Study Cohort of patients with dementia or cognitive dysfunction Monocentric data | 20/15/5 | YES 13 had dementia (4 Alzheimer’s type; 6 vascular dementia; 1 mixed dementia) 7 had mild cognitive impairment | Yes | No | 4 Alzheimer’s type 6 vascular dementia 1 mixed dementia 1 normal pressure hydrocephalus 8 mild cognitive impairment: 5 vascular MCI | YES Brain MRI revealing subcortical lesions. Brain SPECT revealing asymmetrical focal hypoperfusion. | No |
Table 1. Cont.

| 1st Author Year | Study Design | Patients F/M | Cognitive Impairment | Depression | Fatigue | Subset of Cognitive Impairment | Neuro Imaging | Correlation with Extraglandular Manifestations |
|-----------------|--------------|--------------|-----------------------|------------|---------|-------------------------------|--------------|-----------------------------------------------|
| 8 Lin TM, 2018 [27] | Population study Taiwan National Health Insurance Research Database | 4766 | 238 patients had dementia NO information about the type of dementia is present. | No | No | Not specified | Yes | The NHIRD does not contain such parameters such as clinical severity and laboratory data. |
| 9 Omma A, 2018 [28] | Case-control Multicenter data Cross-sectional study | 97/8 | | YES | YES | Not clear | No | Not clear |
| 10 Ye W, 2018 [7] | Cohort study Monocentric data Cross-sectional study | 415 10/1 ratio | | YES | 1.03% 4/415 had cognitive dysfunction | Yes | 10 pts had depression | No | Not reported | YES | Brain MRI | YES | 125/415 pts |
| 11 Koçer B, 2016 [29] | Case-control Monocentric data | 32 0 | Low performance in Clock Drawing, COWAT, PASAT, Colourless Word Reading (Stroop1) and Recognizing Colours (Stroop2) Patterns of STROOP test, AVLT immediate verbal memory (A1) and long-term verbal memory (A7) patterns, BLOT, and in all the patterns of RCFT in PSS patients compared to the healthy control group (p < 0.05) | Yes | SF (pain) 53.44 Hamilton + in 6.69 | Yes | Not reported | YES | SPECT (Hypo perfusion in parietal, temporal, and frontal lobes was 56.3%) | No |
| 12 Wouters EJM, 2012 [30] | Case-control Two-centre data | 294 273/21 | | No | Not reported | Yes | Not reported | Absent | No |
| 13 Hartkamp A, 2004 [31] | Case-control Two-centre data | 60 60/0 | | No | | Yes | MFI; General fatigue and physical fatigue were present in 75%, reduced activity in 63%, and reduced motivation and mental fatigue in 52% | No | | Yes | Cytokine level above the lower range of detection of the assay used was present in 13% of patients for IL2, 5 (8%) for IL6, 32% for IL10, and 83% for TNFa | Absent |
### Table 1. Cont.

| 1st Author Year | Study Design | Patients F/M | Cognitive Impairment | Depression | Fatigue | Subset of Cognitive Impairment | Neuro Imaging | Correlation with Extraglandular Manifestations |
|------------------|--------------|--------------|----------------------|------------|---------|--------------------------------|--------------|---------------------------------------------|
| Blanc F, 2013    | Case-control Monocentric data Prospective data | 25/21 | Yes | 60% | Five patients had dementia in the PSS group. Ten patients had MCI, five had a non-amnestic single domain, and five an amnestic MCI multi-domain. | No | Five patients had dementia. 10 patients had MCI, five had a non-amnestic single domain, and five an amnestic MCI multi-domain | Brain MRI | A trend towards a correlation was found between WML and the severity of cognitive dysfunctions |
| Dziadkowiak E, 2015 | Case-control Monocentric data | 30/29 | No | | MMSE and CDT normal | Yes | Subjective depressed mood >2 w 20% | Not Reported |Absent | Endogenous cognitive event-related potentials (CERPs) |
| Goodchild CE, 2010 | Cohorts pSS and RA Prospective Multicentric (clinics) | 14/14 | No | | | Yes | Mental fatigue 1.74, somatic fatigue 2.83 | Not Reported |Absent | Oral sicca 2.92, ocular sicca 2.36 (profile of discomfort) |
| Lauvsnes MB, 2013 | Case-control Monocentric data | 66/58 | No | | | Yes | BDI (30%) | No | Not reported | MRI revealed a smaller hippocampus volume |
| Hackett K, 2015 | Case-control Cross-sectional Multicentric | 105 ? | Not reported | | Yes | Multivariate analysis (with HAD) 0.428 | Yes | Not reported | Absent | Dryness VAS (multivariate analysis 0.087) |
| Rosado SN, 2018 | Case report | 1/1 | Yes | Neuropsychiatric manifestations associated with severe cognitive dysfunction | Yes | No | Not reported | MRI Normal | Yes | AntirRo, antila +, Schimer test + Weakly positive for IgM anticardiolipin and anti-R2-glycoprotein 1 with negative IgG. |
Table 1. Cont.

| 1st Author Year | Study Design | Patients F/M | Cognitive Impairment | Depression | Fatigue | Subset of Cognitive Impairment | Neuro Imaging | Correlation with Extraglandular Manifestations |
|------------------|--------------|--------------|----------------------|------------|---------|-------------------------------|--------------|-----------------------------------------------|
| 20 Hayashi Y, 2008 [38] | Case report | 1/0/1 | Yes 100% Progressive dementia and gait disturbance | No | No | Yes | MRI, SPECT perfusion imaging for cerebral blood flow revealed regions of decreased uptake in the parietal lobes. Brain MRI and magnetic resonance angiography (MRA) were normal | MRI T1-weighted images with low-intensity lesions, and T2-weighted and FLAIR images with high-intensity lesions in the left frontal white matter, bilateral parietal and left occipital white matter, left thalamus, and right middle cerebellar peduncle, which were not enhanced by Gadolinium No. Saxon and Shirmer tests Scintigraphy of the parotid and submandibular glands, and lip biopsy that revealed many lymphocytes and plasma cells infiltrating the small salivary glands |
| 21 Hirohata M, 2005 [39] | Case report | 1/1/0 | Yes 100% Forgetfulness (memory disturbance) | No | No | Yes | MRI, SPECT perfusion imaging for cerebral blood flow revealed regions of decreased uptake in the parietal lobes. Brain MRI and magnetic resonance angiography (MRA) were normal | MRI T1-weighted images with low-intensity lesions, and T2-weighted and FLAIR images with high-intensity lesions in the left frontal white matter, bilateral parietal and left occipital white matter, left thalamus, and right middle cerebellar peduncle, which were not enhanced by Gadolinium No. Saxon and Shirmer tests Scintigraphy of the parotid and submandibular glands, and lip biopsy that revealed many lymphocytes and plasma cells infiltrating the small salivary glands |

CES-D = Center for Epidemiologic Studies Depression scale; FSS = Fatigue Severity Scale; APLS = Antibodies anti Phospholipid syndrome; MCI: Mild Cognitive Impairment; MRI = Magnetic Resonance Imaging; AVLT = Auditory-Verbal Learning Test; BJLOT = Benton Judgment of Line Orientation Test; RCFT = Recognizing Color Function Test.
3.2. *pSS, Mild Cognitive Impairment (MCI), and Dementia*

Six studies appraised the relationships between *pSS*, MCI, and dementia [22,25–27,32,33]. Yoshikawa et al. published a retrospective study and evaluated a cohort of 20 patients with *pSS* and dementia or cognitive dysfunction in general. Their age ranged from 56 to 92 years. They found that 12 patients were affected by dementia (four by Alzheimer’s type; six by vascular dementia; one by mixed dementia; one by normal pressure hydrocephalus), and eight by MCI (five of them had a vascular MCI). In all patients, brain magnetic resonance imaging (MRI) and single-photon emission computed tomography (SPECT) were performed. A correlation with depression was found, whereas no correlation with other extraglandular manifestations of *pSS* was observed [26].

In a case-control prospective study, Blanc et al. found that among 25 patients with *pSS*, 15 (60%) presented with cognitive dysfunction; five of these had dementia. Dementia was diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders, fourth edition, text revision (DSM-IV-TR). According to Petersen’s criteria, 10 of the patients had MCI (five non-amnestic single domain and five amnestic). Their age ranged from 30 to 74 years. The mean duration of cognitive complaints was 6.1 ± 5.6 years. Neuropsychological symptoms came first for six patients. Brain MRI was performed in all patients, and a trend towards a correlation was found between the severity of cognitive impairment and the degree of white matter lesions (WML) with a $p$-value = 0.03. No cases of MCI or dementia were found in the control group [32].

In a case-control study, Dziadkowiak et al. evaluated 30 consecutive patients with *pSS* (median age of 51 years), and found that cognitive impairment correlated with disease duration and with severity of inflammatory changes [33].

In 2015, Morreale et al. published their data regarding 87 patients with recent (<6 months) diagnosis of *pSS* and found that 31.1% had cognitive dysfunction compatible with dementia. Brain MRI was performed [25].

In 28 patients with *pSS*, Tezcan et al. found that 78.8% had cognitive impairment of the frontal- subcortical type and 11% had a severe cognitive impairment. No neuroimaging evaluation was performed. In two patients, there was no active extraglandular manifestation during neuropsychological assessment [22].

More recently, in a population study based on the Taiwan National Health Insurance Research Database (NHIRD), Lin et al. found that, among 4756 patients with *pSS*, 238 had dementia. However, the type of dementia was not specified. In NHIRD, parameters such as clinical severity or laboratory data are not recorded [27].

In these studies, brain MRI, when performed, mostly showed frontal and subcortical pathological findings. However, in several patients MRI scans were normal.

3.3. *Fatigue and Cognitive Function in pSS*

In *pSS* patients, fatigue prevalence is between 67% and 85 %, and it can be considered a good indicator of systemic activity [40,41]. Indeed, the assessment of fatigue is present in two of the most important *pSS* activity scales, namely the “Sjogren’s syndrome disease activity index (SSDAI)” [42,43] and the “Sjogren’s syndrome systemic clinical activity index (SCAI)” [44]. A strong correlation was observed between the presence of subjective cognitive symptoms and fatigue severity, and dysfunction in attention, executive functions, working memory, and verbal memory among objective cognitive tests [45]. Among the studies included in this review, eight also had assessed fatigue [20,22,28–30,33,34,36]. The case-control study published in 2016 by Kocer et al. was of great interest; 32 patients with *pSS* were evaluated through comprehensive neuropsychological tests and neuroimaging. In the other six studies included in this review, neuroimaging was not performed. Fatigue was evaluated by using the Fatigue Severity Scale (FSS). FSS is a nine-item self-administered instrument. The scores for each item range from one to seven, with the lower score indicating less fatigue. A FSS score ≥4 reliably differentiates subjects with fatigue from controls. In this study, no statistically significant differences were observed in terms of all neuropsychological tests, depression, fatigue severity, health state, and daily-life activities between *pSS*
and control cases without depression. These findings indicate the presence of a pattern of cognitive impairment without the negative effects of depression in patients with pSS. Nevertheless, the authors found a correlation between fatigue and cognitive dysfunction, with a p-value <0.05 when they were compared with the healthy control group. In particular, a significant negative correlation between the Clock Drawing and the SF-36 was observed. However, they highlighted that fatigue may not affect neuropsychological-tests performance in well-selected patients [29]. In the other included studies, a certain terminological confusion was found. In particular, confusion among fatigue, weakness, and stiffness was particularly frequent.

3.4. Laboratory Data and Clinical Manifestations

In the majority of the studies included in this review, correlations between extraglandular manifestations, laboratory data, and cognitive dysfunction were not assessed or not found. Delalande et al.’s study was particularly interesting, because they found that in 47% of patients sicca symptoms were absent [4]. The potential pathogenetic role of antibodies against the NR-2 subtype of N-methyl-D-aspartate (NMDA) receptors was particularly evaluated in the study performed by Lauvsnes et al. The authors found that cognitive dysfunction and depression occurred more frequently in pSS patients with anti-NR2 antibodies than in pSS patients without them. A correlation between anti-NR2 antibodies, cognitive dysfunction, and hippocampus volume was also highlighted in a subgroup of their pSS patients [35].

4. Discussion

This systematic review highlighted that cognitive impairment can occur in patients with pSS. Many individuals reported mild cognitive difficulties, often referred to as the so-called “brain fog”. We know that brain fog is a characteristic of fibromyalgia; some investigators have referred to it as fibro-fog [46,47]. A brain fog has been reported in 50 – 80% of fibromyalgic patients [46–48]. Is the brain fog of fibromyalgic patients identical to that of patients with pSS? Is there a “Sjo-fog”? In this review, it is postulated and argued that brain fog in pSS is not different from that of fibromyalgia. As in fibromyalgia, its physiological basis in pSS is not clearly understood, but it has been suggested to be multifactorial with pain, depression, sleep, and some drugs being the most important determinants [46–49]. In clinical practice, the possibility that brain fog can be related to a concomitant or overlapping fibromyalgia must be carefully considered [49,50].

A possible immune-mediated endothelitis has been hypothesized in brain fog in patients with pSS, but this review did not identify studies confirming this hypothesis. This unmet need should be addressed in ad hoc future studies.

Dementia is less commonly described in the literature, with subcortical dementia as the most frequent clinical finding [20–24]. Furthermore, pSS is common in the elderly [51] and older age can be a common factor with AD. In a nation-wide retrospective population study, which was not included in this review because it did not meet the inclusion criteria, a higher prevalence of AD was found in pSS patients older than 70 years than in non-pSS patients, suggesting that pSS should be considered as a risk factor for AD [52]. In another prospective study, recruiting patients with dementia in a memory clinic, patients with pSS accounted for 7.5% of those with cognitive impairment [23].

This systematic review suggests that four important points must be taken into account in clinical practice:

1) Dementia can occur in patients with pSS. With increasing ageing, subcortical dementia is usually due to vascular brain pathology or synucleinopathies (i.e., Parkinson’s disease and Lewy body disease), but it can also be associated with pSS in a small proportion of cases (5%) [8], although the actual causal mechanisms or relationship remains to be elucidated from current available knowledge.

2) An autoimmune-induced dementia is possible in pSS. Autoimmune dementia is, by definition, reversible. It may be misdiagnosed as a primary, degenerative dementia, leading to serious therapeutic errors.

3) Normal findings in brain MRI are frequent in patients with pSS.
4) Cognitive dysfunction can be the first clinical manifestation of pSS.

Hence, it is very important that clinicians look for sicca syndrome or for laboratory data suggestive of pSS when direct observation and neurologic tests detect problems with information processing, attention, memory, or executive function, even if brain MRI is normal or in the presence of a few WML. SPECT assessment should be considered, as it revealed a hypoperfusion in parietal, temporal, and frontal lobes in more than 50% of patients having normal MRI brain when cognitive dysfunction was present. This SPECT pattern was present only in 17% of pSS patients without cognitive dysfunction [20–39,53].

The first observation of a correlation between CNS involvement and laboratory data is in the series of eight patients described by Alexander et al. in 1982, in which a direct pathogenetic role of the antiRo (SSA) antibodies was suggested [54]. However, cognitive dysfunction may occur even in the seronegative forms of pSS [20,54], and this must be taken into account in clinical practice.

NR2 receptors are present in particularly high-density in the hippocampus. Binding of anti-NR2 antibodies to these receptors causes neuronal death through an increase of intracellular levels of calcium. Anti-NR2 antibodies may play a pathogenetic role in cognitive dysfunction in pSS, and correlation between their levels and the severity of cognitive dysfunction have been suggested [32]. However, this hypothesis should be confirmed in multicenter, large studies.

Finally, the roles of cryoglobulinemia and antiphospholipid syndrome were more than anecdotal in this review [18].

Fatigue is a frequent and destabilizing manifestation in patients with pSS and it can influence their cognitive performances. This review identified only one good-quality article that evaluated this relationship, confirming a bidirectional interference between fatigue and cognitive functions [29]. The interference of pain was not always taken into account. For example, testing patients during pSS relapses should favor it. From the review, it is not possible to tease out the influence of fatigue and pain on cognitive functions in patients with pSS.

Our review identified areas that demand further insight. First, some of the included studies did not report the severity of pSS [17,21,23,25,28,29], and few correlations between disease severity and cognitive function were possible. Second, the evaluation of the pathogenetic role of comorbid diseases was often absent [17,21–25]. The lack of information on the type of dementia represented a third critical point in the majority of the included studies [7,20,22,24–28,30–34].

5. Conclusions

Cognitive dysfunction can be present in patients with pSS, and, in some cases, it is the first clinical manifestation.

In most cases, a brain fog or MCI are present. Occasionally, pSS can cause an autoimmune dementia that would be reversible by definition. However, the relationship between pSS and degenerative dementias, such as AD, is not clear, even if some investigators have hypothesized that pSS could be a risk factor. In elderly onset SS, older age can be a common risk factor.

When cognitive impairment is diagnosed in a middle-aged patient, a search for sicca syndrome or for laboratory data suggestive of pSS should be considered. However, the possibility that sicca symptoms can be absent in pSS patients with cognitive dysfunction, as well as that cognitive dysfunction can be present in seronegative forms of pSS, must be taken into account.

The routine assessment of cognitive function in patients with pSS seems advisable, and will inform the future studies designed to explore some of the knowledge gaps highlighted by this review.

**Supplementary Materials:** The following are available online at http://www.mdpi.com/2076-3425/9/4/85/s1. Box 1: Full search terms used together with the results of the searches in MEDLINE.

**Author Contributions:** Conceptualization, C.M. and J.S.-M.; methodology, C.M., J.S.-M., and M.I.; software, M.I.; validation, C.M., E.M.-S., M.K., and M.I.; formal analysis, C.M., E.M.-S., and M.K.; investigation, M.I., E.M.-S., C.M.; data curation, E.M.-S., C.M., and M.K.; writing and original draft preparation, C.M.; writing – review and editing, J.S.-M., M.I., M.K., E.M.-S., and C.M.; supervision, J.S.-M. and C.M.; project administration, M.I.

**Funding:** This research received no external funding.
Conflicts of Interest: The Authors declare no conflict of interest.

References
1. Patel, R.; Shahane, A. The epidemiology of Sjögren’s syndrome. *Clin. Epidemiol.* 2014, 6, 247–255.
2. Qin, B.; Wang, J.; Yang, Z.; Yang, M.; Ma, N.; Huang, F.; Zhong, R. Epidemiology of primary Sjögren’s syndrome: A systematic review and meta-analysis. *Ann. Rheum. Dis.* 2015, 74, 1983–1989. [CrossRef] [PubMed]
3. Mariette, X.; Criswell, L.A. Primary Sjögren’s Syndrome. *N. Engl. J. Med.* 2018, 378, 931–939. [CrossRef] [PubMed]
4. McCoy, S.S.; Baer, A.N. Neurological Complications of Sjögren’s Syndrome: Diagnosis and Management. *Curr. Treat. Options Rheumatol.* 2017, 3, 275–288. [CrossRef] [PubMed]
5. Perzyńska-Mazan, J.; Maślińska, M.; Gasik, R. Neurological manifestations of primary Sjögren’s syndrome. *Reumatologia* 2018, 56, 99–105. [CrossRef] [PubMed]
6. Gono, T.; Kawaguchi, Y.; Katsumata, Y.; Takagi, K.; Tochimoto, A.; Baba, S.; Okamoto, Y.; Ota, Y.; Yamanaka, H. Clinical manifestations of neurological involvement in primary Sjögren’s syndrome. *Clin. Rheumatol.* 2011, 30, 485–490. [CrossRef] [PubMed]
7. Ye, W.; Chen, S.; Huang, X.; Qin, W.; Zhang, T.; Zhu, X.; Lin, C.; Wang, X. Clinical features and risk factors of neurological involvement in Sjögren’s syndrome. *BMC Neurosci.* 2018, 19, 26. [CrossRef] [PubMed]
8. Moreira, I.; Teixeira, F.; Martins Silva, A.; Vasconcelos, C.; Farinha, F.; Santos, E. Frequent involvement of central nervous system in primary Sjögren syndrome. *Rheumatol. Int.* 2015, 35, 289–294. [CrossRef] [PubMed]
9. Posso-Osorio, I.; Naranjo-Escobar, J.; Loaiza, D.M.; Polo, M.; Echeverri, A.; Tobon, G.J. Neurological involvement in primary Sjogren’s syndrome. *Curr. Rheumatol. Rev.* 2018. [CrossRef]
10. Manzo, C.; Serra-Mestres, J. Considerations on fibrofog and fibromyalgic discognition in older patients. *Giornale Italiano di Reumatologia Clinica* 2016, 3, 59–75.
11. Serra-Mestres, J. Problemas de memoria no debidos a demencia: Conceptos y mecanismos. *Inf. Psiquiatr.* 2016, 224, 13–20.
12. Helme, C.; Hegarty, R.S.M.; Stebbings, S.; Treherne, G.J. “I actually just really need to stop work sometimes”: Exploring fatigue-related barriers to employment among people with rheumatic diseases. *Musculoskelet. Care* 2018. [CrossRef] [PubMed]
13. Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G. The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLoS Med.* 2009, 6, e1000097. [CrossRef] [PubMed]
14. Vitali, C.; Bombardieri, S.; Jonsson, R.; Moutsopoulos, H.M.; Alexander, E.L.; Carsons, S.E.; Daniels, T.E.; Fox, P.C.; Fox, R.I.; Kassan, S.S.; et al. Classification criteria for Sjögren’s syndrome: A revised version of the American-European Consensus Group. *Ann. Rheum. Dis.* 2002, 61, 554–558. [CrossRef]
15. Shiboski, S.C.; Shiboski, C.H.; Criswell, L.A.; Baer, A.N.; Challacombe, S.; Lanfranchi, H.; Schaad, M.; Umehara, H.; Vivino, F.; Zhao, Y.; et al. American College of Rheumatology Classification Criteria for Sjögren’s Syndrome: A Data-Driven, Expert Consensus Approach in the SICCA Cohort. *Arthritis Care Res.* 2012, 64, 475–487. [CrossRef]
16. Shiboski, C.H.; Shiboski, S.C.; Seror, R.; Criswell, L.A.; Labetoulle, M.; Lietman, T.M.; Rasmussen, A.; Scofield, H.; Vitali, C.; Bowman, S.J.; et al. 2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren’s Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts. *Arthritis Rheumatol.* 2017, 69, 35–45. [CrossRef]
17. Le Goff, M.; Corneil, D.; Jousse-Joulin, S.; Costa, S.; Guellec, D.; Marhadour, T.; Le Berre, R.; Genestet, S.; Cochener, B.; Boisrame-Gastrin, S.; et al. Comparison of 2002 AECG and 2016 ACR/EULAR classification criteria and added value of salivary gland ultrasonography in a patient cohort with suspected primary Sjögren’s syndrome. *Arthritis Res. Ther.* 2017, 19, 269. [CrossRef]
18. Franceschini, F.; Cavazzana, I.; Andreoli, L.; Tincani, A. The 2016 classification criteria for primary Sjogren’s syndrome: What’s new? *BMC Med.* 2017, 15, 69. [CrossRef] [PubMed]
19. Stang, A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of non-randomized studies in metaanalyses. *Eur. J. Epidemiol.* 2010, 25, 603–605. [CrossRef]
20. Segal, B.M.; Pogatchnik, B.; Holker, E.; Liu, H.; Sloan, J.; Rhodus, N.; Moser, K.L. Primary Sjogren’s syndrome: Cognitive symptoms, mood, and cognitive performance. *Acta Neurol. Scand.* 2012, 125, 272–278. [CrossRef] [PubMed]

21. Le Guern, V.; Belin, C.; Henegar, C.; Moroni, C.; Maillet, D.; Lacau, C.; Dumas, J.L.; Vigneron, N.; Guillemin, L. Cognitive function and 99mTc-ECD brain SPECT are significantly correlated in patients with primary Sjogren syndrome: A case-control study. *Ann. Rheum. Dis.* 2010, 69, 132–137. [CrossRef] [PubMed]

22. Tezcan, M.E.; Kocer, E.B.; Haznedaroğlu, S.; Sonmez, C.; Nercan, R.; Yucel, A.A.; Irkeç, C.; Bitik, B.; Goker, B. Primary Sjögren’s syndrome is associated with significant cognitive dysfunction. *Int. J. Rheum. Dis.* 2016, 19, 981–988. [CrossRef] [PubMed]

23. Delalande, S.; de Seze, J.; Fauchais, A.-L.; Hachulla, E.; Stojkovic, T.; Ferriby, D.; Dubucquoi, S.; Pruvo, J.-P.; Vermersch, P.; Hatron, P.-Y. Neurologic manifestations in primary Sjögren syndrome: A study of 82 patients. *Medicine* 2004, 83, 280–291. [CrossRef] [PubMed]

24. Rodrigues, D.N.; Hora, J.S.; Salgado, M.C. A short neuropsychological evaluation of patients with primary Sjögren’s syndrome. *Arq. Neuropsiquiatr.* 2014, 72, 38–43. [CrossRef] [PubMed]

25. Morreale, M.; Francia, A.; Marchione, P.; Manuppella, F.; Giacomini, P. Intracranial hemodynamic changes in primary Sjögren syndrome: A transcranial Doppler case-control study. *Neurol. Sci.* 2015, 36, 1589–1595. [CrossRef] [PubMed]

26. Yoshikawa, K.; Hatate, J.; Toratani, N.; Sugiyama, S.; Shimizu, Y.; Takahashi, T.; Ito, T.; Fukunaga, R. Prevalence of Sjogren’s syndrome with dementia in a memory clinic. *J. Neurol. Sci.* 2012, 322, 217–221. [CrossRef]

27. Lin, T.-M.; Chen, W.-S.; Sheu, J.-J.; Chen, Y.-H.; Chen, J.-H.; Chang, C.-C. Autoimmune rheumatic diseases increase dementia risk in middle-aged patients: A nationwide cohort study. *PLoS ONE* 2018, 13, e0186475. [CrossRef]

28. Omma, A.; Tecer, D.; Kucuksahin, O.; Sandikci, S.C.; Yildiz, F.; Erten, S. Do the European League Against Rheumatism (EULAR) Sjögren’s syndrome outcome measures correlate with impaired quality of life, fatigue, anxiety and depression in primary Sjögren’s syndrome? *Arch. Med. Sci.* 2018, 14, 830–837. [CrossRef] [PubMed]

29. Koçer, B.; Tezcan, M.E.; Batur, H.Z.; Haznedaroğlu, S.; Göker, B.; İrkeç, C.; Çetinkaya, R. Cognition, depression, fatigue, and quality of life in primary Sjögren’s syndrome: Correlations. *Brain Behav.* 2016, 6, e00586. [CrossRef]

30. Wouters, E.J.M.; van Leeuwen, N.V.; Bossema, E.R.; Kruize, A.A.; Bootsma, H.; Bijlsma, J.W.J.; Geenen, R. Physical activity and physical activity cognitions are potential factors maintaining fatigue in patients with primary Sjogren’s syndrome. *Ann. Rheum. Dis.* 2012, 71, 668–673. [CrossRef]

31. Hartkamp, A.; Geenen, R.; Bijl, M.; Kruize, A.A.; Godaert, G.L.R.; Derksen, R.H.W.M. Serum cytokine levels related to multiple dimensions of fatigue in patients with primary Sjögren’s syndrome. *Ann. Rheum. Dis.* 2004, 63, 1335–1337. [CrossRef]

32. Blanc, F.; Longato, N.; Jung, B.; Kleitz, C.; Di Bitonto, L.; Cretin, B.; Collongues, N.; Sordet, C.; Fleury, M.; Poindron, V.; et al. Cognitive Dysfunction and Dementia in Primary Sjögren’s Syndrome. *ISRN Neurol.* 2013, 19, 501327. [CrossRef] [PubMed]

33. Dziadkowiak, E.; Sebastian, A.; Wiland, P.; Waliszewska-Prosol, M.; Zagrajek, M.; Ejma, M. Endogenous event-related potentials in patients with primary Sjögren’s syndrome without central nervous system involvement. *Scand. J. Rheumatol.* 2015, 44, 487–494. [CrossRef]

34. Goodchild, C.E.; Trebarne, G.J.; Booth, D.A.; Bowman, S.J. Daytime patterning of fatigue and its associations with the previous night’s discomfort and poor sleep among women with primary Sjögren’s syndrome or rheumatoid arthritis. *Musculoskelet. Care* 2010, 8, 107–117. [CrossRef] [PubMed]

35. Lauvsnes, M.B.; Maroni, S.S.; Appenzeller, S.; Beyer, M.K.; Greve, O.J.; Kvaloy, J.T.; Barbo, E.; Goransson, L.G.; Tjensvoll, A.B.; Omdal, R. Memory dysfunction in primary Sjögren’s syndrome is associated with anti-NR2 antibodies. *Arthritis Rheum.* 2013, 65, 3209–3217. [CrossRef] [PubMed]

36. Hackett, K.L.; Deary, I.; Deane, K.H.; Newton, J.L.; Ng, W.-F.; Rapley, T. Experience of sleep disruption in primary Sjögren’s syndrome: A focus group study. *Br. J. Occup. Ther.* 2018, 81, 218–226. [CrossRef] [PubMed]

37. Rosado, S.N.; Silveira, V.; Reis, A.I.; Gordinho, A.; Noronha, C. Catatonia and psychosis as manifestations of primary Sjögren’s syndrome. *Eur. J. Case Rep. Intern. Med.* 2018, 5. [CrossRef] [PubMed]
38. Hayashi, Y.; Kimura, A.; Kato, S.; Koumura, A.; Sakurai, T.; Tanaka, Y.; Hozumi, I.; Sunden, Y.; Orba, Y.; Saw, H.; et al. Progressive multifocal leukoencephalopathy and CD4+ T-lymocytopenia in a patient with Sjögren syndrome. *J. Neurol. Sci.* 2008, 268, 195–198. [CrossRef]
39. Hirohata, M.; Yasukawa, Y.; Ishida, C.; Komai, K.; Yamada, M. Reversible cortical lesions in primary Sjögren syndrome presenting with meningoencephalitis as an initial manifestation. *J. Neurol. Sci.* 2008, 268, 195–198. [CrossRef]
40. Arends, S.; Meiners, P.M.; Moerman, R.V.; Kroese, F.G.; Brouwer, E.; Spijkervet, F.K.; Vissink, A.; Bootsma, H. Physical fatigue characterises patient experience of primary Sjögren’s syndrome. *Clin. Exp. Rheumatol.* 2017, 35, 255–261. [PubMed]
41. Bodeweis, I.L.A.; van der Spek, P.J.; Leon, L.G.; Wijkhuijs, A.J.M.; van Helden-Meeuwsen, C.G.; Tas, L.; Schreurs, M.W.J.; van Dale, P.L.A.; Katsikis, P.D.; Versnel, M.A. Fatigue in Sjögren’s Syndrome: A Search for Biomarkers and Treatment Targets. *Front. Immunol.* 2019, 10, 312. [CrossRef] [PubMed]
42. Seror, R.; Ravaud, P.; Bowman, S.J.; Baron, G.; Tzioufas, A.; Theander, E.; Gottenberg, J.-E.; Bootsma, H.; Mariette, X.; Vitali, C. EULAR Sjögren’s syndrome disease activity index: Development of a consensus systemic disease activity index for primary Sjögren’s syndrome. *Ann. Rheum. Dis.* 2010, 69, 1103–1109. [CrossRef]
43. Seror, R.; Bowman, S.J.; Brito-Zeron, P.; Theander, E.; Bootsma, H.; Tzioufas, A.; Gottenberg, J.E.; Roman-Casals, M.; Dorner, T.; Ravaud, P.; et al. EULAR Sjögren’s syndrome disease activity index (ESSDAI): A user guide. *RMD Open* 2015, 1, e000022. [CrossRef]
44. Bowman, S.J.; Sutcliffe, N.; Isenberg, D.A.; Goldblatt, F.; Adler, M.; Price, E.; Canavan, A.; Hamburger, J.; Richards, A.; Regan, S.M.; et al. Sjögren’s Systemic Clinical Activity Index (SCAI)-A systemic disease activity measure for use in clinical trials in primary Sjögren’s syndrome. *Rheumatology* 2007, 46, 1845–1851. [CrossRef]
45. Coates, T.; Slavotinek, J.P.; Rischmueller, M.; Schultz, D.; Anderson, C.; Dellamelva, M. Cerebral white matter lesions in primary Sjögren’s syndrome: A controlled study. *J. Rheumatol.* 1999, 26, 1301–1305.
46. Ambrose, K.R.; Gracely, R.H.; Glass, J.M. Fibromyalgia dyscognition: Concepts and issue. *Reumatismo* 2012, 64, 206–215. [CrossRef]
47. Torta, R.G.V.; Tesio, V.; Ieraci, V.; Castelli, L.; Zizzi, F.B. Fibro-fog. *Clin. Exp. Rheumatol.* 2016, 34 (Suppl. 96), S6–S8.
48. Glass, J.M.; Park, D.C. Cognitive dysfunction in fibromyalgia. *Curr. Rheumatol. Rep.* 2001, 3, 123–127. [CrossRef]
49. Choi, B.Y.; Oh, H.J.; Lee, Y.J.; Song, Y.W. Prevalence and clinical impact of fibromyalgia in patients with primary Sjögren’s syndrome. *Clin. Exp. Rheumatol.* 2016, 34 (Suppl. 96), 59–63.
50. Kang, J.H.; Lin, H.C. Comorbidities in patients with primary Sjögren’s syndrome: A registry-based case-control study. *J. Rheumatol.* 2010, 37, 1188–1194. [CrossRef]
51. Manzo, C.; Maslinska, M. Primary Sjögren’s syndrome in the elderly: Does age of onset make a difference? *EMJ Rheumatol.* 2018, 5, 75–82. [CrossRef] [PubMed]
52. Segal, B.M.; Pogatchnik, B.; Henn, L.; Radser, K.; Sivils, K.M. Pain severity and neuropathic pain symptoms in primary Sjögren’s syndrome: A comparison study of seropositive and seronegative Sjögren’s syndrome patients. *Arthritis Care Res.* 2013, 65, 1291–1298. [CrossRef] [PubMed]

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).